1. DeMatteo R. et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. The Lancet. Published online March 19, 2009. Accessed March 2009. http://www.thelancet.com/
2. Van den Abbeele A, Benjamin R, Blanke C et al. Clinical Management of GIST. Recurrence patterns and prognostic factors for survival. 2003; 1–24.
3. Demetri GD, Benjamin RS, Blanke CD et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST) – update of NCCN clinical practice guidelines. J Natl Compr Cancer Network, 2007; 2 (suppl. 1): S1–26.
4. Gleevec® (imatinib mesylate) tablets prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
5. Joensuu H. Current perspectives on the epidemiology of gastrointestinal stromal tumors. Eur J Cancer Suppl 2006; 4 (3): 4–9.
6. The World Factbook. European Union Population. CIA.gov; June 2005. Available from: https://www.cia.gov/library/publications/the-world-factbook/print/ee.html. Accessed March 2009.